EUCTR2009-017603-28-IT进行中（未招募）不适用
Aprepitant for prevention of acute and delayed nausea and vomiting: a phase III, double-blind, randomized, palcebo-controlled trial in patients receiving a high-emetogenic dose of cyclophosphamide for peripheral blood stem cells harvesting - ND
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male or female patients ≥ 18 years of age -Patient is able to understand study procedure and agrees to participate in the study by giving written informed consent. -Patient is scheduled to receive a highly emetogenic cyclophosphamide IV chemotherapy (3 g/m2) for autologous PBSC harvesting -Karnofsky score ≥60 -Normal epatic function (bilirubin < 1.5 mg/dl) ed renal function (creatinin < 2 mg/dl). -Normal ECG -HBV-, HCV- and HIV- negative -Negative urine pregnancy test for women of childbearing age
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Serious accompanying disorders or impaired organ function (in particular impaired left ventricular function or severe cardiac arrhythmias) - Platelets < 100 000/mm3 , leukocytes < 2 500/mm3 - Known hypersensitivity to the medications to be used - Known HIV-positivity - Active hepatitis infection - Pregnancy and lactation period - Not application of inclusion criteria
研究者
相似试验
进行中（未招募）
不适用
Aprepitant in the prevention of delayed emesis induced by moderately emetogenic chemotherapy (cyclophosphamide + anthracycline) in breast cancer patients: a double-blind randomized study - Aprepitant in the prevention of delayed emesispatients with breast cancer receiving chemotherapyMedDRA version: 9.1Level: SOCClassification code 10017947MedDRA version: 9.1Level: HLTClassification code 10028817EUCTR2008-001237-95-ITAZIENDA OSPEDALIERA S. MARIA DI TERNI800
Unknown
3 期
Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells HarvestingNauseaVomitingNCT01088022Azienda Ospedaliera di Perugia120
进行中（未招募）
不适用
Application of Aprepitant as salvage prophylaxis after failure of a conventional antiemetic therapy during moderately emetogenic chemotherapy in gastrointestinal cancer - EMEND_GIChemotherapy-induced nasuea and vomiting (CINV)EUCTR2004-003783-30-DETechnical Unversity of Munich
已完成
3 期
The safety and efficacy of Aprepitant to the prevention of chemotherapy-induced nausea and vomitingIRCT20200819048455N1Iran University of Medical Sciences85
进行中（未招募）
不适用
A new therapeutic approach to prevent acute complications in type 2 diabetes: The effect of the combination of the GLP-1 Analog Liraglutide and Insulin LEvemir® against the cOnventional insulin therapy: GALILEOdiabetes mellitus type 2, inadequate metabolic control, indication for insulin therapymyocardial lipid accumulation and left-ventricular function, retinal changes, microabluminuria, beta-cell-function, endothelial dysfunctionMedDRA version: 14.1Level: PTClassification code 10012607Term: Diabetes mellitus inadequate controlSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10012689Term: Diabetic retinopathySystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: HLTClassification code 10012654Term: Diabetic complications cardiovascularSystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 14.1Level: PTClassification code 10012647Term: Diabetic cardiomyopathySystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 14.1Level: HLTClassification code 10012658Term: Diabetic complications renalSystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 14.1Level: HLTClassification code 10012657Term: Diabetic complications ophthalmicSystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 14.1Level: PTClassification code 10054044Term: Diabetic microangiopathySystem Organ Class: 10047065 - Vascular disordersMedDRA version: 14.1Level: HLGTClassification code 10012653Term: Diabetic complicationsSystem Organ Class: 10014698 - Endocrine disordersEUCTR2012-001208-39-ATMedizinische Universität Wien, Univ.Klinik für Innere Medizin III, Abt.f.Endokrinologie und Stoffwechsel